Revised SPC: Herceptin (trastuzumab) 600 mg Solution for Injection in Vial -

Revised SPC: Herceptin (trastuzumab) 600 mg Solution for Injection in Vial
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Cancers | Family planning
Summary
Trastuzumab may persist in the circulation for up to 7 months (previously stated 2 weeks); this has led to respective amendments in how long women of child-bearing potential should be advised to use contraception for and how long anthracycline-based therapy should be avoided for.
UKMi comment
Further interaction information has also been added – with information from various studies to suggest that trastuzumab has no impact on the pharmacokinetics of carboplatin, and that doxorubicin, paclitaxel and carboplatin have no effect on the pharmacokinetics of trastuzumab.
Related links: